Drug–device combination products are becoming increasingly prevalent, with many lasting years beyond the expiration date of primary and secondary patents on the drug itself. It is unknown how common ...
While the concept of a combination product is not new, these unique healthcare products (drug plus device, biological plus device, drug plus biological product, or drug plus device plus biological ...
On 21 May 2024, the European Medicines Agency (“EMA”) published a revised version of the Questions & Answers for applicants, Marketing Authorisation Holders of medicinal products and notified bodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback